Dipylon puts $3.8m into heart monitor launch
This article was originally published in Clinica
Executive Summary
Swedish heart monitoring device company Dipylon Medical has secured SKr27.5m ($3.8m) in a series A financing round. The capital, which was provided by Dipylon's manufacturing and technology licensing partner CMA Microdialysis, will go towards the initial launch of the Dipylon cardiac catheter. The product was CE marked in January, and is designed to provide continuous metabolic measurements of the heart muscle inside the coronary sinus. The new capital will also be used to support more extensive international studies of the technology. Prior to this round, Solna-based Dipylon had received SKr0.5m in seed funding from business angel group Escritura.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.